<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3532">
  <stage>Registered</stage>
  <submitdate>25/04/2012</submitdate>
  <approvaldate>25/04/2012</approvaldate>
  <nctid>NCT01585753</nctid>
  <trial_identification>
    <studytitle>MARCH Vascular Endothelium Substudy</studytitle>
    <scientifictitle>Maraviroc Switch Vascular Endothelium (VE) Substudy: a Substudy of MARCH</scientifictitle>
    <utrn />
    <trialacronym>MARCH VE</trialacronym>
    <secondaryid>MARCH-Kirby VE substudy</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular Disease</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - NRTI + PI
Treatment: drugs - maraviroc + PI
Treatment: drugs - maraviroc + NRTI

Arm 1 - NRTI and PI

Arm 2 - Maraviroc + PI

Arm 3 - maraviroc + NRTI


Treatment: drugs: NRTI + PI
tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir

Treatment: drugs: maraviroc + PI
maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir

Treatment: drugs: maraviroc + NRTI
maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean change in small arterial elasticity (SAE) as measure by pulse wave tonometry - measured at 6 timepoints week 0, 4, 12, 24, 48, 96</outcome>
      <timepoint>96 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome> Mean change in large arterial elasticity (LAE) as measure by pulse wave tonometry - measured at 6 timepoints, week 0,4,12,24,48,96</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Changes from baseline in selected soluble markers of immune activation, coagulation, vascular and platelet function - stored bloods from the main study will be used to explore changes in vascular biomarkers</outcome>
      <timepoint>96 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Enrolled prior to treatment in the parent study;

          -  Provision of written, informed consent for participation in the substudy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known supraventricular tachycardia such as atrial flutter and/or fibrillation that
             precludes the measurement of pulse wave using tonometry.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>34</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St. Vincent's Hospital - Sydney</hospital>
    <postcode>2010 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a substudy of MARCH, in which we are exploring the changes in the vascular
      endothelium using pulse wave tonometry (a non invasive measure of cardiac health) to measure
      the changes in small and large arterial elasticity in participants of the MARCH study who
      switch to maraviroc-based regimens over 96 weeks of follow-up.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01585753</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sarah L Pett, FRACP,FRCPE,PhD</name>
      <address>Kirby Institute, UNSW</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>